Literature DB >> 29388067

Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential.

Dharambir Kashyap1, Hardeep Singh Tuli2, Vivek Kumar Garg3, Neelam Goel4, Anupam Bishayee5.   

Abstract

MicroRNAs (miRNAs) are the non-coding class of minute RNA molecules that negatively control post-transcriptional regulation of various functional genes. These miRNAs are transcribed from the loci present in the introns of functional or protein-coding genes, exons of non-coding genes, or even in the 3'-untranslated region (3'-UTR). They have potential to modulate the stability or translational efficiency of a variety of target RNA [messenger RNA (mRNA)]. The regulatory function of miRNAs has been elucidated in several pathological conditions, including neurological (Alzheimer's disease and Parkinson's disease) and cardiovascular conditions, along with cancer. Importantly, miRNA identification in cancer progression and invasion has evolved as an incipient era in cancer treatment. Several studies have shown the influence of miRNAs on various cancer processes, including apoptosis, invasion, metastasis and angiogenesis. In particular, apoptosis induction in tumor cells through miRNA has been extensively studied. The biphasic mode (up- and down-regulation) of miRNA expression in apoptosis and other cancer processes has already been determined. The findings of these studies could be utilized to develop potential therapeutic strategies for the management of various cancers. The present review critically describes the oncogenic and tumor suppressor role of miRNAs in apoptosis and other cancer processes, therapy resistance, and use of their presence in the body fluids as biomarkers.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29388067     DOI: 10.1007/s40291-018-0316-1

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  331 in total

Review 1.  Structure and zymogen activation of caspases.

Authors:  Mrudula Donepudi; Markus G Grütter
Journal:  Biophys Chem       Date:  2002-12-10       Impact factor: 2.352

2.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.

Authors:  Fulya Yaman Agaoglu; Müge Kovancilar; Yavuz Dizdar; Emin Darendeliler; Stefan Holdenrieder; Nejat Dalay; Ugur Gezer
Journal:  Tumour Biol       Date:  2011-01-28

3.  MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer.

Authors:  Haitao Guan; Zhijun Dai; Yuguang Ma; Zhongwei Wang; Xiaoxu Liu; Xijing Wang
Journal:  Int J Mol Med       Date:  2016-04-11       Impact factor: 4.101

4.  miR‑410 regulates apoptosis by targeting Bak1 in human colorectal cancer cells.

Authors:  Chunyuan Liu; Aihong Zhang; Lei Cheng; Yang Gao
Journal:  Mol Med Rep       Date:  2016-05-13       Impact factor: 2.952

5.  MicroRNA-320 family is downregulated in colorectal adenoma and affects tumor proliferation by targeting CDK6.

Authors:  Toshihiro Tadano; Yoichi Kakuta; Shin Hamada; Yosuke Shimodaira; Masatake Kuroha; Yoko Kawakami; Tomoya Kimura; Hisashi Shiga; Katsuya Endo; Atsushi Masamune; Seiichi Takahashi; Yoshitaka Kinouchi; Tooru Shimosegawa
Journal:  World J Gastrointest Oncol       Date:  2016-07-15

6.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

7.  miR‑181b‑5p mediates TGF‑β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells.

Authors:  Xuetao Li; Jing Han; Haizhen Zhu; Lina Peng; Zhengtang Chen
Journal:  Int J Oncol       Date:  2017-05-17       Impact factor: 5.650

8.  Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer.

Authors:  Ali Flores-Pérez; Laurence A Marchat; Sergio Rodríguez-Cuevas; Verónica Bautista-Piña; Alfredo Hidalgo-Miranda; Elena Aréchaga Ocampo; Mónica Sierra Martínez; Carlos Palma-Flores; Miguel A Fonseca-Sánchez; Horacio Astudillo-de la Vega; Erika Ruíz-García; Juan Antonio González-Barrios; Carlos Pérez-Plasencia; María L Streber; César López-Camarillo
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

9.  MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42.

Authors:  Yong-Xia Wang; Yan-Ru Chen; Shan-Shan Liu; Ya-Ping Ye; Hong-Li Jiao; Shu-Yang Wang; Zhi-Yuan Xiao; Wen-Ting Wei; Jun-Feng Qiu; Li Liang; Wen-Ting Liao; Yan-Qing Ding
Journal:  Oncotarget       Date:  2016-12-20

10.  MicroRNA-212 inhibits the proliferation, migration and invasion of renal cell carcinoma by targeting X-linked inhibitor of apoptosis protein (XIAP).

Authors:  Chaohui Gu; Zhiyu Wang; Zhibo Jin; Guanru Li; Yiping Kou; Zhankui Jia; Jinjian Yang; Fengyan Tian
Journal:  Oncotarget       Date:  2017-09-08
View more
  9 in total

1.  MicroRNA-6852 suppresses cell proliferation and invasion via targeting forkhead box J1 in gastric cancer.

Authors:  Hui Yu; Jing Zhang; Qu Wen; Yi Dai; Wanli Zhang; Fen Li; Juan Li
Journal:  Exp Ther Med       Date:  2018-08-02       Impact factor: 2.447

2.  Altered expression of apoptosis-related, circulating cell-free miRNAs in children with familial Mediterranean fever: a cross-sectional study.

Authors:  Emin Murat Karpuzoglu; Rabia Miray Kisla Ekinci; Sibel Balci; Atil Bisgin; Mustafa Yilmaz
Journal:  Rheumatol Int       Date:  2020-03-05       Impact factor: 2.631

3.  Exosome-enriched fractions from MS B cells induce oligodendrocyte death.

Authors:  Joyce A Benjamins; Liljana Nedelkoska; Hanane Touil; Paul M Stemmer; Nicholas J Carruthers; Bhanu P Jena; Akshata R Naik; Amit Bar-Or; Robert P Lisak
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-04-09

Review 4.  Potential Mechanisms of Action of Curcumin for Cancer Prevention: Focus on Cellular Signaling Pathways and miRNAs.

Authors:  Man Wang; Shuai Jiang; Li Zhou; Fei Yu; Han Ding; Peifeng Li; Meng Zhou; Kun Wang
Journal:  Int J Biol Sci       Date:  2019-05-07       Impact factor: 6.580

Review 5.  Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential.

Authors:  Dharambir Kashyap; Vivek Kumar Garg; Hardeep Singh Tuli; Mukerrem Betul Yerer; Katrin Sak; Anil Kumar Sharma; Manoj Kumar; Vaishali Aggarwal; Sardul Singh Sandhu
Journal:  Biomolecules       Date:  2019-05-06

Review 6.  Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements.

Authors:  Vaishali Aggarwal; Dharambir Kashyap; Katrin Sak; Hardeep Singh Tuli; Aklank Jain; Ashun Chaudhary; Vivek Kumar Garg; Gautam Sethi; Mukerrem Betul Yerer
Journal:  Int J Mol Sci       Date:  2019-02-02       Impact factor: 5.923

Review 7.  Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.

Authors:  Dharambir Kashyap; Vivek Kumar Garg; Elise N Sandberg; Neelam Goel; Anupam Bishayee
Journal:  Pharmaceutics       Date:  2021-04-17       Impact factor: 6.321

Review 8.  Anti-Inflammatory and Anticancer Properties of Birch Bark-Derived Betulin: Recent Developments.

Authors:  Hardeep Singh Tuli; Katrin Sak; Dhruv Sanjay Gupta; Ginpreet Kaur; Diwakar Aggarwal; Nidarshana Chaturvedi Parashar; Renuka Choudhary; Mukerrem Betul Yerer; Jagjit Kaur; Manoj Kumar; Vivek Kumar Garg; Gautam Sethi
Journal:  Plants (Basel)       Date:  2021-12-03

9.  Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.

Authors:  Juan de Los Santos-Jiménez; José A Campos-Sandoval; Clara Márquez-Torres; Nieves Urbano-Polo; David Brøndegaard; Mercedes Martín-Rufián; Carolina Lobo; Ana Peñalver; María C Gómez-García; Janet Martín-Campos; Carolina Cardona; Laura Castilla; Felipe da Costa Souza; Tzuling Cheng; Juan A Segura; Francisco J Alonso; Rui Curi; Alison Colquhoun; Ralph J DeBerardinis; Javier Márquez; José M Matés
Journal:  J Biomed Sci       Date:  2021-02-20       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.